Table I.
Demographic details of the study groups.
| Variables | Primary tumor (N=123) (%) | Deposits of cancer cells (N=25) (%) | Liver metastases (N=15) (%) |
|---|---|---|---|
| Age (years) | |||
| <60 | 29 (23.7) | 6 (24) | 1 (6.6) |
| >60 | 94 (76.3) | 19 (76) | 14 (93.4) |
| Sex | |||
| Female | 48 (39.0) | 10 (40) | 5 (33.3) |
| Male | 75 (61.0) | 15 (60) | 10 (66.7) |
| Localization | |||
| Right-side | 13 (10.5) | 3 (12) | 2 (13.3) |
| Transverse | 5 (4.0) | 1 (4) | 1 (6.6) |
| Left-side | 4 (3.2) | 1 (4) | 2 (13.3) |
| Sigmoid | 21 (17.3) | 5 (20) | 1 (6.6) |
| Rectum | 80 (65.0) | 15 (60) | 9 (60.2) |
| Tumor growth | |||
| Expanding | 103 (83.7) | 20 (80) | 13 (98.7) |
| Infiltrate | 20 (16.3) | 5 (20) | 2 (1.3) |
| Tumor size | |||
| <2.5 cm | 20 (16.3) | 3 (12) | 2 (1.3) |
| 2.5–5.0 cm | 81 (65.8) | 20 (80) | 13 (98.7) |
| >5.0 cm | 22 (17.9) | 2 (8) | 0 (0) |
| TNM stage | |||
| 1 | 17 (13.8) | 0 (0) | 0 (0) |
| 2 | 43 (34.9) | 0 (0) | 0 (0) |
| 3 | 58 (47.1) | 21 (84) | 0 (0) |
| 4 | 2 (4.2) | 4 (16) | 15 (100) |
| Lymph node metastasis | |||
| Absent | 65 (52.8) | 1 (4) | 6 (39.8) |
| Present | 58 (47.2) | 24 (96) | 9 (60.2) |
| Distant metastasis | |||
| Absent | 123 (100) | 21 (84) | 0 (0) |
| Present | 0 (0) | 4 (16) | 15 (100) |
| No. of metastases | |||
| Single | 0 (0) | 3 (75) | 8 (53.4) |
| Multiple | 0 (0) | 1 (25) | 7 (46.6) |
| Distant metastasis size (mm) | |||
| <5 | 0 (0) | 1 (33.3) | 7 (46.6) |
| >5 | 0 (0) | 2 (66.7) | 8 (53.4) |
| Tumour deposits | |||
| Absent | 123 (100) | 0 (0) | 11 (63.7) |
| Present | 0 (0) | 25 (100) | 4 (36.3) |
| Preoperative treatment | |||
| Yes | 40 (32.6) | 7 (28) | 3 (2) |
| No | 83 (67.4) | 18 (72) | 12 (80) |
| Type of preoperative treatment | |||
| CHT | 5 (14) | 2 (28.5) | 0 (0) |
| RHT | 29 (70) | 1 (14.2) | 3 (100) |
| RHT+CHT | 6 (16) | 4 (57.3) | 0 (0) |
| Preoperative treatment response | |||
| SD | 13 (26) | 3 (60) | 2 (66.7) |
| PR | 17 (24) | 2 (40) | 1 (33.3) |
| Postoperative treatment | |||
| Yes | 46 (37.3) | 5 (20) | 8 (53.4) |
| No | 77 (62.7) | 20 (80) | 7 (46.6) |
| Type of postoperative treatment | |||
| CHT | 40 (86.9) | 5 (100) | 6 (75) |
| RHT | 2 (4.5) | 0 (0) | 1 (12.5) |
| RHT+CHT | 4 (8.6) | 0 (0) | 1 (12.5) |
| Disease-free survival | |||
| <6 months | 38 (30.8) | 9 (36) | 6 (40) |
| 6–12 months | 27 (22.9) | 5 (20) | 3 (20) |
| >12 months | 57 (46.3) | 11 (44) | 6 (40) |
RHT, radiotherapy; CHT, chemotherapy; SD, stable disease; PR, progression of disease.